PROOF | GenomeWeb

PROOF

With data from the CanPREDDICT study, the partners will develop a test to predict the rate of disease progression in patients with chronic kidney disease.

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced a collaboration to validate the Centre of Excellence for the Prevention of Organ Failure's (PROOF Centre) assay for organ rejection in heart transplant patients.

Canada's Prevention of Organ Failure Centre of Excellence has granted HTG Molecular Diagnostics exclusive rights to commercialize a risk stratification test the center has been developing to better personalize treatment for chronic obstructive pulmonary disease.

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics said today that it has licensed exclusive rights from Vancouver's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) to commercialize gene expression tests for prognosis of COPD patients who will experience frequent lung a

NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure, or PROOF Centre, and IO Informatics today announced a deal to develop a web-based software application addressing chronic heart, lung, and kidney disease.

Canada's Prevention of Organ Failure Centre of Excellence in Vancouver is using C$1.5 million (US$1.5 million) in funding from Genome British Columbia and other groups to develop a molecular test intended to personalize treatment for chronic obstructive pulmonary disease.

The partners will develop and validate the centre's biomarker-based tests on Luminex's xMAP platform.

Tech Transfer Tidbits

Premium

Kauffman Foundation, MIT, BioAMPS, University of Colorado, Endo Pharma, Harvard, Galapagos, Flanders Institute of Biotechnology, and more …

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.